Loxagen

Loxagen is a biotechnology company that translates mechanistic discoveries into small molecule therapies for stroke, cancer, and metabolic diseases. The company utilizes a high-throughput discovery platform to identify and rationally design allosteric inhibitors for lipoxygenase isozymes, such as ALOX15 and ALOX12, by screening marine natural product libraries and the NIH Chemical Genomics Center inhibitor library. This approach targets specific binding constraints to address diseases with significant unmet needs where current standards of care may be inadequate.

The company aims to solve complex medical challenges, including aneurysmal subarachnoid hemorrhage, ischemic stroke, pancreatic cancer, and type 1 diabetes. By leveraging an experienced executive team and advisory board composed of industry veterans and academic experts from institutions like Harvard and Johns Hopkins, Loxagen has progressed lead programs through IND-enabling studies. The company is supported by non-dilutive funding from various organizations and is currently working toward IND submissions and phase 1 clinical trials for its pipeline candidates.